Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

X65f5effa.07f7.4ed3.9e0a.3a0d9d451474

· cohortA1

662135f0-07fa-581a-9f48-6e6c56bccea3

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortA1
subtype
cohortA1
age_years
80

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.330
  • ALLOGRAFT_REJECTION+0.320
  • INTERFERON_GAMMA_RESPONSE+0.290
  • MITOTIC_SPINDLE+0.140
  • IL6_JAK_STAT3_SIGNALING+0.110
  • COMPLEMENT+0.060
  • IL2_STAT5_SIGNALING+0.060
  • INFLAMMATORY_RESPONSE+0.060
  • KRAS_SIGNALING_DN+0.030
  • WNT_BETA_CATENIN_SIGNALING+0.030

Top 10 suppressed

  • MYC_TARGETS_V1-0.580
  • OXIDATIVE_PHOSPHORYLATION-0.560
  • MTORC1_SIGNALING-0.550
  • UNFOLDED_PROTEIN_RESPONSE-0.510
  • PROTEIN_SECRETION-0.490
  • CHOLESTEROL_HOMEOSTASIS-0.460
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
  • MYC_TARGETS_V2-0.450
  • TGF_BETA_SIGNALING-0.450
  • E2F_TARGETS-0.440

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2208971
melanoma-umap@29
0.902
2s0122234
melanoma-umap@29
0.899
3ERR2208899
melanoma-umap@29
0.899
4TCGA-MN-A4N5-01A-11R-A24X-07
lung-landscapes@6
cohortA10.898
5MNG882
mng-umap@100
0.893
6AUR-AFSP-TTP1-A-8-0-R-A741-41
breast-umap@18
D0.893
7MNG1098
mng-umap@100
0.890
8AUR-AG0J-TTP1-A-1-0-R-A741-41
breast-umap@18
D0.887
9bae6fdb5-9df3-433c-9a4c-e5c159a62bc6
colon-landscapes@1
0.887
10MNG1248
mng-umap@100
0.883

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 11 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.330Inavolisib— uncovered
ALLOGRAFT_REJECTION0.320Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.290Idelalisib— uncovered
MITOTIC_SPINDLE0.140Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.110Inavolisib— uncovered
COMPLEMENT0.060Inavolisib— uncovered
IL2_STAT5_SIGNALING0.060Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.060Idelalisib— uncovered
KRAS_SIGNALING_DN0.030Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.030Inavolisib— uncovered
APICAL_SURFACE0.010Temsirolimus— uncovered